Press Releases from October 3, 2018
advertisement
- Results from Two Phase 3 Studies Show Lilly’s Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint in People with Type 1 and Type 2 Diabetes. See also Ultra-rapid insulin improves postprandial glucose levels in type 1, type 2 diabetes.
- Health Canada approves TRESIBA® for children with Type 1 diabetes.
- Abbott′s FreeStyle® Libre 2, with Optional Real-Time Alarms, Secures CE Mark for Use in Europe.
- Beyond Type 1 Receives $300,985 Helmsley Charitable Trust Grant for DKA Awareness Campaign.